Logo image of RCAT

RED CAT HOLDINGS INC (RCAT) Stock Fundamental Analysis

NASDAQ:RCAT - Nasdaq - US75644T1007 - Common Stock

8.46  -0.09 (-1.11%)

Premarket: 8.97 +0.51 (+6.03%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RCAT. RCAT was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. Both the profitability and financial health of RCAT have multiple concerns. RCAT shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

RCAT had negative earnings in the past year.
RCAT had a negative operating cash flow in the past year.
RCAT had negative earnings in each of the past 5 years.
In the past 5 years RCAT always reported negative operating cash flow.
RCAT Yearly Net Income VS EBIT VS OCF VS FCFRCAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

RCAT's Return On Assets of -74.99% is on the low side compared to the rest of the industry. RCAT is outperformed by 90.83% of its industry peers.
RCAT's Return On Equity of -141.75% is on the low side compared to the rest of the industry. RCAT is outperformed by 89.17% of its industry peers.
Industry RankSector Rank
ROA -74.99%
ROE -141.75%
ROIC N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
RCAT Yearly ROA, ROE, ROICRCAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

RCAT's Gross Margin of 10.92% is on the low side compared to the rest of the industry. RCAT is outperformed by 76.67% of its industry peers.
RCAT's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for RCAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5YN/A
RCAT Yearly Profit, Operating, Gross MarginsRCAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

3

2. Health

2.1 Basic Checks

RCAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCAT has more shares outstanding
Compared to 5 years ago, RCAT has more shares outstanding
The debt/assets ratio for RCAT has been reduced compared to a year ago.
RCAT Yearly Shares OutstandingRCAT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RCAT Yearly Total Debt VS Total AssetsRCAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

RCAT has an Altman-Z score of 12.86. This indicates that RCAT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.86, RCAT belongs to the top of the industry, outperforming 89.17% of the companies in the same industry.
A Debt/Equity ratio of 0.44 indicates that RCAT is not too dependend on debt financing.
RCAT's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. RCAT is outperformed by 67.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 12.86
ROIC/WACCN/A
WACC10.55%
RCAT Yearly LT Debt VS Equity VS FCFRCAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

RCAT has a Current Ratio of 1.43. This is a normal value and indicates that RCAT is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of RCAT (1.43) is worse than 80.83% of its industry peers.
A Quick Ratio of 0.57 indicates that RCAT may have some problems paying its short term obligations.
The Quick ratio of RCAT (0.57) is worse than 92.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.57
RCAT Yearly Current Assets VS Current LiabilitesRCAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

7

3. Growth

3.1 Past

RCAT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.85%.
Looking at the last year, RCAT shows a very strong growth in Revenue. The Revenue has grown by 49.70%.
Measured over the past years, RCAT shows a very strong growth in Revenue. The Revenue has been growing by 176.68% on average per year.
EPS 1Y (TTM)-3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
Revenue 1Y (TTM)49.7%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.82%

3.2 Future

Based on estimates for the next years, RCAT will show a very strong growth in Earnings Per Share. The EPS will grow by 48.46% on average per year.
Based on estimates for the next years, RCAT will show a very strong growth in Revenue. The Revenue will grow by 123.37% on average per year.
EPS Next Y54.1%
EPS Next 2Y48.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year105.93%
Revenue Next 2Y151.19%
Revenue Next 3Y123.37%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RCAT Yearly Revenue VS EstimatesRCAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M
RCAT Yearly EPS VS EstimatesRCAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.1 -0.2 -0.3 -0.4

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCAT. In the last year negative earnings were reported.
RCAT is valuated quite expensively with a Price/Forward Earnings ratio of 103.68.
The rest of the industry has a similar Price/Forward Earnings ratio as RCAT.
The average S&P500 Price/Forward Earnings ratio is at 24.44. RCAT is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 103.68
RCAT Price Earnings VS Forward Price EarningsRCAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCAT Per share dataRCAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as RCAT's earnings are expected to grow with 48.46% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.46%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for RCAT!.
Industry RankSector Rank
Dividend Yield N/A

RED CAT HOLDINGS INC

NASDAQ:RCAT (1/21/2025, 8:23:18 PM)

Premarket: 8.97 +0.51 (+6.03%)

8.46

-0.09 (-1.11%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)12-16 2024-12-16/amc
Earnings (Next)N/A N/A
Inst Owners13.99%
Inst Owner Change0.21%
Ins Owners21.24%
Ins Owner Change-8.95%
Market Cap678.15M
Analysts85
Price Target10.2 (20.57%)
Short Float %13.29%
Short Ratio0.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-102.21%
Min EPS beat(2)-108.33%
Max EPS beat(2)-96.08%
EPS beat(4)0
Avg EPS beat(4)-106.49%
Min EPS beat(4)-145.1%
Max EPS beat(4)-76.47%
EPS beat(8)1
Avg EPS beat(8)-89.52%
EPS beat(12)2
Avg EPS beat(12)-134.79%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-46.32%
Min Revenue beat(2)-63.42%
Max Revenue beat(2)-29.22%
Revenue beat(4)0
Avg Revenue beat(4)-25.17%
Min Revenue beat(4)-63.42%
Max Revenue beat(4)-1.15%
Revenue beat(8)2
Avg Revenue beat(8)-20.22%
Revenue beat(12)2
Avg Revenue beat(12)-34.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)42.86%
PT rev (3m)122.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.23%
Revenue NY rev (3m)16.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 103.68
P/S 41.18
P/FCF N/A
P/OCF N/A
P/B 25.09
P/tB 1086.38
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)0.08
Fwd EY0.96%
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.21
BVpS0.34
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.99%
ROE -141.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.92%
FCFM N/A
ROA(3y)-36.1%
ROA(5y)-55.7%
ROE(3y)-39.94%
ROE(5y)-95.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.21%
GM growth 5YN/A
F-Score3
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.08%
Cap/Sales 1.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.57
Altman-Z 12.86
F-Score3
WACC10.55%
ROIC/WACCN/A
Cap/Depr(3y)137.29%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.59%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-80%
EPS Next Y54.1%
EPS Next 2Y48.46%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)49.7%
Revenue growth 3Y52.8%
Revenue growth 5Y176.68%
Sales Q2Q%-60.82%
Revenue Next Year105.93%
Revenue Next 2Y151.19%
Revenue Next 3Y123.37%
Revenue Next 5YN/A
EBIT growth 1Y-5.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.81%
EBIT Next 3Y56.58%
EBIT Next 5YN/A
FCF growth 1Y13.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.2%
OCF growth 3YN/A
OCF growth 5YN/A